Overview
Financials
Units: $M (per-share in $, ratios in %)Revenue & profit
Margins
Valuation
Multiples at each fiscal year end (annual) and current (TTM)Valuation history
Segments
Revenue breakdown (annual, $B). Segments depend on each year’s disclosure.By product
By region
Dividends & earnings
Annual dividend per share ($, split-adjusted)
EPS (diluted), last 16 quarters ($)
Company info
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.